Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir
Main Author: | |
---|---|
Publication Date: | 2007 |
Other Authors: | , , , , , , , , |
Format: | Article |
Language: | eng |
Source: | Repositório Institucional da UNIFESP |
Download full: | http://repositorio.unifesp.br/handle/11600/3523 http://dx.doi.org/10.1590/S1413-86702007000100006 |
Summary: | This study evaluates clinical, virological and immunological responses to antiretroviral (ARV) therapy based on Lopinavir/ritonovir (LPV/r) in previously protease -inhibitor-experienced children. The study included 29 Brazilian children (median age = 5.91 years) who had failed previous ARV therapy and had begun a regimen based on LPV/r. At 12 months follow-up, a good virological response to LPV/r therapy was defined as achieving an undetectable viral load or as a decrease in plasma HIV RNA levels to > 1 log. A good immunological response was defined as an increase in CD4+ cell count from baseline sufficient to attain a better CDC immune stage classification. The number of infectious episodes 12 months before and 12 months after beginning LPV/r was assessed. Sixteen (55.2%) and 19 (65.5%) of 29 patients exhibited good virological and immunological responses, respectively. Baseline CD4+ values (>500) predicted both virological and immunological responses (p<0.05). Older children were less likely to develop an immunological response (p<0.001) than younger children. Nine children receiving 3 ARV drugs plus LPV/r showed an immunological response (100%) compared to 10/20 (50%) children receiving 2 drugs plus LPV/r (p=0.01). A lower number (n<5) of infectious episodes was noted after 12 months follow-up in children using the LPV/r regimen (p=0.006). There was a positive correlation between children whose baseline CD4+ values were greater than 500 cells/mm³ and virological responses. Although virological responses to therapy were seen in about half the children (55.2%), the use of HAART containing LPV/r provided clinical and immmunological benefits. |
id |
UFSP_b7d2508d9329dbba316ef2467596b1f0 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/3523 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Machado, Daisy Maria [UNIFESP]Gouvêa, Aida de Fátima Thomé Barbosa [UNIFESP]Cardoso, Maria ReginaBeltrão, Suênia Vasconcelos [UNIFESP]Cunegundes, Kelly Simone [UNIFESP]Bononi, Fabiana [UNIFESP]Almeida, Fernanda [UNIFESP]Cavalheiro, Kaline [UNIFESP]Angelis, Daniela Souza Araújo deSucci, Regina Célia de Menezes [UNIFESP]Universidade Federal de São Paulo (UNIFESP)São Paulo University Faculty of Public HealthUniversidade de São Paulo (USP)2015-06-14T13:36:41Z2015-06-14T13:36:41Z2007-02-01Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 11, n. 1, p. 16-19, 2007.1413-8670http://repositorio.unifesp.br/handle/11600/3523http://dx.doi.org/10.1590/S1413-86702007000100006S1413-86702007000100006.pdfS1413-8670200700010000610.1590/S1413-86702007000100006WOS:000253997600006This study evaluates clinical, virological and immunological responses to antiretroviral (ARV) therapy based on Lopinavir/ritonovir (LPV/r) in previously protease -inhibitor-experienced children. The study included 29 Brazilian children (median age = 5.91 years) who had failed previous ARV therapy and had begun a regimen based on LPV/r. At 12 months follow-up, a good virological response to LPV/r therapy was defined as achieving an undetectable viral load or as a decrease in plasma HIV RNA levels to > 1 log. A good immunological response was defined as an increase in CD4+ cell count from baseline sufficient to attain a better CDC immune stage classification. The number of infectious episodes 12 months before and 12 months after beginning LPV/r was assessed. Sixteen (55.2%) and 19 (65.5%) of 29 patients exhibited good virological and immunological responses, respectively. Baseline CD4+ values (>500) predicted both virological and immunological responses (p<0.05). Older children were less likely to develop an immunological response (p<0.001) than younger children. Nine children receiving 3 ARV drugs plus LPV/r showed an immunological response (100%) compared to 10/20 (50%) children receiving 2 drugs plus LPV/r (p=0.01). A lower number (n<5) of infectious episodes was noted after 12 months follow-up in children using the LPV/r regimen (p=0.006). There was a positive correlation between children whose baseline CD4+ values were greater than 500 cells/mm³ and virological responses. Although virological responses to therapy were seen in about half the children (55.2%), the use of HAART containing LPV/r provided clinical and immmunological benefits.Federal University of São PauloSão Paulo University Faculty of Public HealthUSP FM Institute of Tropical MedicineUNIFESP, EPMSciELO16-19engBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious DiseasesHIVChildrenHAARTlopinavirFactors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavirinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALS1413-86702007000100006.pdfapplication/pdf53989${dspace.ui.url}/bitstream/11600/3523/1/S1413-86702007000100006.pdfb3e7f9ef22e95370d9f8db6bc8b2b2f0MD51open accessTEXTS1413-86702007000100006.pdf.txtS1413-86702007000100006.pdf.txtExtracted texttext/plain21109${dspace.ui.url}/bitstream/11600/3523/2/S1413-86702007000100006.pdf.txt4947478cf375f20f7985c542eefa65b3MD52open access11600/35232022-09-19 22:29:20.089open accessoai:repositorio.unifesp.br:11600/3523Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:14:42.367413Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir |
title |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir |
spellingShingle |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir Machado, Daisy Maria [UNIFESP] HIV Children HAART lopinavir |
title_short |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir |
title_full |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir |
title_fullStr |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir |
title_full_unstemmed |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir |
title_sort |
Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir |
author |
Machado, Daisy Maria [UNIFESP] |
author_facet |
Machado, Daisy Maria [UNIFESP] Gouvêa, Aida de Fátima Thomé Barbosa [UNIFESP] Cardoso, Maria Regina Beltrão, Suênia Vasconcelos [UNIFESP] Cunegundes, Kelly Simone [UNIFESP] Bononi, Fabiana [UNIFESP] Almeida, Fernanda [UNIFESP] Cavalheiro, Kaline [UNIFESP] Angelis, Daniela Souza Araújo de Succi, Regina Célia de Menezes [UNIFESP] |
author_role |
author |
author2 |
Gouvêa, Aida de Fátima Thomé Barbosa [UNIFESP] Cardoso, Maria Regina Beltrão, Suênia Vasconcelos [UNIFESP] Cunegundes, Kelly Simone [UNIFESP] Bononi, Fabiana [UNIFESP] Almeida, Fernanda [UNIFESP] Cavalheiro, Kaline [UNIFESP] Angelis, Daniela Souza Araújo de Succi, Regina Célia de Menezes [UNIFESP] |
author2_role |
author author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) São Paulo University Faculty of Public Health Universidade de São Paulo (USP) |
dc.contributor.author.fl_str_mv |
Machado, Daisy Maria [UNIFESP] Gouvêa, Aida de Fátima Thomé Barbosa [UNIFESP] Cardoso, Maria Regina Beltrão, Suênia Vasconcelos [UNIFESP] Cunegundes, Kelly Simone [UNIFESP] Bononi, Fabiana [UNIFESP] Almeida, Fernanda [UNIFESP] Cavalheiro, Kaline [UNIFESP] Angelis, Daniela Souza Araújo de Succi, Regina Célia de Menezes [UNIFESP] |
dc.subject.eng.fl_str_mv |
HIV Children HAART lopinavir |
topic |
HIV Children HAART lopinavir |
description |
This study evaluates clinical, virological and immunological responses to antiretroviral (ARV) therapy based on Lopinavir/ritonovir (LPV/r) in previously protease -inhibitor-experienced children. The study included 29 Brazilian children (median age = 5.91 years) who had failed previous ARV therapy and had begun a regimen based on LPV/r. At 12 months follow-up, a good virological response to LPV/r therapy was defined as achieving an undetectable viral load or as a decrease in plasma HIV RNA levels to > 1 log. A good immunological response was defined as an increase in CD4+ cell count from baseline sufficient to attain a better CDC immune stage classification. The number of infectious episodes 12 months before and 12 months after beginning LPV/r was assessed. Sixteen (55.2%) and 19 (65.5%) of 29 patients exhibited good virological and immunological responses, respectively. Baseline CD4+ values (>500) predicted both virological and immunological responses (p<0.05). Older children were less likely to develop an immunological response (p<0.001) than younger children. Nine children receiving 3 ARV drugs plus LPV/r showed an immunological response (100%) compared to 10/20 (50%) children receiving 2 drugs plus LPV/r (p=0.01). A lower number (n<5) of infectious episodes was noted after 12 months follow-up in children using the LPV/r regimen (p=0.006). There was a positive correlation between children whose baseline CD4+ values were greater than 500 cells/mm³ and virological responses. Although virological responses to therapy were seen in about half the children (55.2%), the use of HAART containing LPV/r provided clinical and immmunological benefits. |
publishDate |
2007 |
dc.date.issued.fl_str_mv |
2007-02-01 |
dc.date.accessioned.fl_str_mv |
2015-06-14T13:36:41Z |
dc.date.available.fl_str_mv |
2015-06-14T13:36:41Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 11, n. 1, p. 16-19, 2007. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/3523 http://dx.doi.org/10.1590/S1413-86702007000100006 |
dc.identifier.issn.none.fl_str_mv |
1413-8670 |
dc.identifier.file.none.fl_str_mv |
S1413-86702007000100006.pdf |
dc.identifier.scielo.none.fl_str_mv |
S1413-86702007000100006 |
dc.identifier.doi.none.fl_str_mv |
10.1590/S1413-86702007000100006 |
dc.identifier.wos.none.fl_str_mv |
WOS:000253997600006 |
identifier_str_mv |
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 11, n. 1, p. 16-19, 2007. 1413-8670 S1413-86702007000100006.pdf S1413-86702007000100006 10.1590/S1413-86702007000100006 WOS:000253997600006 |
url |
http://repositorio.unifesp.br/handle/11600/3523 http://dx.doi.org/10.1590/S1413-86702007000100006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Brazilian Journal of Infectious Diseases |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
16-19 |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/3523/1/S1413-86702007000100006.pdf ${dspace.ui.url}/bitstream/11600/3523/2/S1413-86702007000100006.pdf.txt |
bitstream.checksum.fl_str_mv |
b3e7f9ef22e95370d9f8db6bc8b2b2f0 4947478cf375f20f7985c542eefa65b3 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460267123802112 |